The National Institute for Health and Care Excellence has authorised belantamab mafodotin for routine use on the National Health Service in England, making the UK the first country to deploy the so-called “Trojan horse” therapy against multiple myeloma. Belantamab mafodotin, developed by GlaxoSmithKline, is an antibody-drug conjugate that delivers a potent chemotherapeutic payload directly inside malignant plasma cells. Combined with bortezomib and dexamethasone, clinical trials showed the regimen extends median progression-free survival to almost three years, compared with about 13 months on standard care. NHS England estimates roughly 1,500 adults whose disease has relapsed or failed to respond to first-line treatment will be eligible each year. The drug is administered as a 30-minute infusion every three weeks and is expected to offer a kinder side-effect profile than conventional chemotherapy, though patients may experience temporary eye irritation or blurred vision. Discovered partly at GSK’s Stevenage research hub and first tested in London, the therapy’s approval underscores the NHS’s strategy of fast-tracking targeted treatments that can prolong quality life for patients with otherwise incurable cancers.